Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience.
Marc Ryan Matrana
No relevant relationships to disclose
Aditya V. Shetty
No relevant relationships to disclose
Bradley J. Atkinson
No relevant relationships to disclose
Lianchun Xiao
No relevant relationships to disclose
Paul G. Corn
No relevant relationships to disclose
Randall E. Millikan
No relevant relationships to disclose
Eric Jonasch
No relevant relationships to disclose
Nizar M. Tannir
No relevant relationships to disclose